ROIV — Roivant Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $21.55bn
- $18.02bn
- $8.26m
Annual cashflow statement for Roivant Sciences, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -924 | -1,115 | 4,231 | -357 | -398 |
| Depreciation | |||||
| Non-Cash Items | 217 | 247 | -5,038 | -420 | 266 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 29.5 | 6.34 | 19 | -77 | -622 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -678 | -843 | -765 | -839 | -750 |
| Capital Expenditures | -17.4 | -12.7 | -1.38 | -4.6 | -8.21 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 321 | -31.6 | 5,205 | -1,762 | -674 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 303 | -44.3 | 5,204 | -1,766 | -682 |
| Financing Cash Flow Items | 292 | -13.1 | -43.7 | -37.2 | -9.37 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 307 | 499 | 419 | -1,220 | 134 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -67.6 | -382 | 4,858 | -3,825 | -1,295 |